Tromsø, Norway, 9[th] December 2022 - ArcticZymes Technologies ASA (OSE: AZT)
upscales the production of ArcticZymes Proteinase and launches ArcticZymes
Proteinase Glycerol FREE

ArcticZymes Technologies (AZT) has successfully upscaled the production of
ArcticZymes Proteinase. This will allow the Company to meet growing demand from
new and existing customers, thereby strengthening the CompanyŽs position as a
supplier of critical components in molecular diagnostics and biomanufacturing
applications.

Additionally, AZT has launched a glycerol-free formulation of the proteinase.
This was facilitated by the upscaling of the proteinase enzyme. This glycerol
-free formulation will enable the Company to support customers requiring a
lyophilization compatible formulation of the proteinase for use in high
throughput molecular diagnostic workflows.

Together the upscaled production capacity and addition of a glycerol-free
formulation, greatly increases the market reach for ArcticZymes Proteinase
products, both being instrumental factors for sales growth while ensuring a
reliable and relevant product offering to existing and new customers.

ArcticZymes Technologies ASA, CEO, Jethro Holter said:

"The novel features of ArcticZymes Proteinase have already enabled customers to
circumvent technical barriers that other enzymes such as Proteinase K cannot
overcome in molecular diagnostics workflows. In biomanufacturing there is a
growing interest in ArcticZymes Proteinase for potential use in gene therapy
related applications."

For more information, please contact:

ArcticZymes Technologies
CEO, Jethro Holter        Tel: +47 46 85 91 46
CFO, Børge Sørvoll        Tel: +47 95 29 01 87
                            ir@arcticzymes.com

About ArcticZymes Technologies ASA

ArcticZymes Technologies is a Norwegian life sciences company focused on the
development, manufacturing and commercialization of novel recombinant enzymes
for use in molecular research, In Vitro Diagnostics (IVD) and biomanufacturing.

Listed on the Oslo Stock Exchange since 2005 originally under the [Biotec]
ticker, as Biotec Pharmacon. The company rebranded as ArcticZymes Technologies
in 2020 under the [AZT] ticker. Its headquarters are based in Tromsø, Norway, at
the SIVA Innovation Centre.

ArcticZymes Technologies' IP and capabilities are protected via a large
portfolio of patents.

For more information, please visit the website: www.arcticzymes.com